Compare Home Depot Inc (HD) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Home Depot Inc trades at $346.41 (market cap $353.46B), while Regeneron Pharmaceuticals Inc trades at $795.3 (market cap $82.06B). The key difference: Home Depot Inc is far larger — about 4.3× Regeneron Pharmaceuticals Inc's market cap, and Home Depot Inc pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| HD | REGN | |
|---|---|---|
Market Cap | $353.46B | $82.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $812.27 |
52-Week Low | $297.51 | $555.51 |
Enterprise Value | $415.01B | $76.77B |
Dividend Yield | 2.63% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $347.22, down 1.01% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue grew to $159.51 billion in 2025, though net income margin declined to 8.41%. Recent earnings show mixed results, with a Q2 2026 EPS estimate of $4.73. Analyst consensus is bullish with a $371.25 price target, supported by institutional activity and a $2.33 dividend payment scheduled for June 2026.
The stock offers long-term value with strong profitability (ROE 128.38%) and analyst optimism, but faces risks from weakening housing demand and margin pressure. Upside potential exists if Pro business growth offsets macroeconomic headwinds, though high valuation multiples (P/E 25.18) warrant caution amid rising interest rates.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
